Its main goal is to contribute to the development of the research projects carried out at CIMA, for which it provides complete support in the development of any experiment involving large-scale analysis of DNA or RNA of humans and other organisms. The tasks carried out include:
Experimental design. Guidance on deciding the sample size, study design and method planning.
Data analysis. Bioinformatics processing is carried out on the data obtained using different high-performance technological platforms employed in the area of genomics and proteomics (microarrays, sequencing, PCR, etc.). These analyses include standardization, statistical analysis and representation of the results.
The most common analyses include:
Differential gene expression, miRNAs and lncRNAs. The source technology of the experiments may be microarrays (Affymetrix, Agilent), large-scale PCRs (TLDAs from Applied Biosystems) or RNA-seq (Illumina, Ion Torrent).
Studies on genotyping and DNA copy number variation with microarrays (Affymetrix) or DNA sequencing (Illumina).
Characterization of alternative splicing from the data obtained in microarray experiments (Affymetrix) or RNA-seq (Illumina).
Protein-DNA interactions from experiments of immunoprecipitation and microarrays (ChIP-chip) or sequencing (ChIP-seq).
DNA methylation patterns in experiments with microarrays (Illumina Infinium).
More recently, shotgun and semi-quantitative high-resolution proteomics data analysis protocols have been developed.
Assistance in the interpretation of results. Once the relevant genes are selected, studies on biological functional assignment are carried out. This type of analyses can be very broad and may vary depending on the specific goals of each study.
Proyectos de I+D en Salud. AES 2013 a Plataformas de Apoyo a la Investigación en Ciencias y Tecnologías de la Salud
Convocatoria: Proyectos de I+D en Salud. AES 2013 a Plataformas de Apoyo a la Investigación en Ciencias y Tecnologías de la Salud.
Título: “Plataforma de recursos biomoleculares y bioinformáticos, PRB2”.
I. P.: Victor Segura.
Duración: 4 años (prorrogado un año más).
F. Inicio: 01/01/2014 F. Fin: 31/12/2018
Subvención: 345.100 €
Financiado: Por el Instituto de Salud Carlos III y cofinanciado por el Fondo Europeo de Desarrollo Regional (FEDER) “Una manera de hacer Europa”.
Biomedical innovation in the 21st century depends to a great extent on the easy
access to sophisticated omics and bioinformatics technologies and on the
availability of large numbers of biological samples and/or its associated data. Being
aware of this urgent need and to support the development of the molecular
medicine, the Spanish government has committed itself to create outstanding
technology platforms that provide cutting edge technologies and knowhow to the
To this end, the Biomolecular and Bioinformatics Resources Platform (Plataforma
de Recursos Biomoleculares y Bioinformáticos, PRB2) has been created with a
structure that consists of three technology platforms - ProteoRed (proteomics),
CeGen (genomics), INB (bioinformatics) - and two biobanks: BNADN (DNA bank)
and BNLC (cell lines bank).
The PRB2 entangle different complementary disciplines that allow the efficient
management of complex investigations in biomedicine. State of the art technology
is offered to the scientific community in a comprehensive manner, always with the
support of top scientist in their respective specialties, who facilitate the design of the experiment, the analytical process as well as the data processing and
interpretation. This multidisciplinary configuration enables the study of human
biology in health and disease from a systems biology perspective, leading to a
better understanding of complex pathogenic mechanisms and based on them, to
the identification of novel biomarkers and therapeutic targets. Therefore, the PRB2
democratizes the utilization of challenging technology within the biomedical and
medical communities paving the way to the development of innovative clinical
interventions customized to the necessities of each patient according to their
"Our facility has the necessary goal of technological innovation, which is achieved in the context of national and international projects", Dr. Mikel Hernáez, manager of the platform.